Shenzhen Forward Pharmaceuticals

Forward Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, dedicated to the development of best-in-class and first-in-class small molecule drugs for oncology. The company's research focuses on overcoming resistance mechanisms in targeted therapies, particularly in the field of lung cancer and hematological malignancies. Its lead asset, FWD-1502, is a highly selective inhibitor of EGFR and HER2 exon 20 insertions, which represents a significant unmet need in non-small cell lung cancer. Additionally, the company is advancing FWD-1301, a next-generation Bruton tyrosine kinase (BTK) inhibitor. Forward Pharmaceuticals is supported by prominent venture capital firms and maintains a robust internal discovery engine.